Short Interest in Vaccinex, Inc. (NASDAQ:VCNX) Increases By 157.1%

Vaccinex, Inc. (NASDAQ:VCNX) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 16,200 shares, an increase of 157.1% from the March 31st total of 6,300 shares. Currently, 3.0% of the company’s shares are short sold. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is presently 1.2 days.

Hedge Funds Weigh In On Vaccinex

An institutional investor recently raised its position in Vaccinex stock. Worth Venture Partners LLC raised its stake in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 417.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 717,559 shares of the company’s stock after purchasing an additional 578,764 shares during the period. Worth Venture Partners LLC owned 16.31% of Vaccinex worth $811,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.11% of the company’s stock.

Vaccinex Price Performance

NASDAQ:VCNX opened at $5.83 on Friday. The firm has a market cap of $7.17 million, a PE ratio of -0.06 and a beta of 0.74. The firm has a 50 day simple moving average of $7.33 and a 200-day simple moving average of $9.50. Vaccinex has a 1-year low of $4.43 and a 1-year high of $100.80.

Vaccinex (NASDAQ:VCNX) last issued its quarterly earnings results on Tuesday, April 2nd. The company reported ($39.40) earnings per share for the quarter.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.